What is Leerink Partnrs’ Estimate for PRCT FY2028 Earnings?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Research analysts at Leerink Partnrs boosted their FY2028 earnings per share estimates for shares of PROCEPT BioRobotics in a research note issued to investors on Monday, October 28th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.12 per share for the year, up from their previous estimate of $0.10. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.88) per share.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. The business had revenue of $58.40 million during the quarter, compared to analyst estimates of $53.30 million. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 37.85%. The firm’s revenue was up 66.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) earnings per share.

PRCT has been the topic of a number of other reports. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Bank of America upped their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. TD Cowen lifted their price target on PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a report on Monday, September 16th. Piper Sandler restated an “overweight” rating and issued a $75.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Finally, Wells Fargo & Company lifted their target price on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $88.40.

PROCEPT BioRobotics Stock Down 3.8 %

PROCEPT BioRobotics stock opened at $93.03 on Wednesday. The firm’s 50 day moving average price is $77.01 and its two-hundred day moving average price is $67.73. The firm has a market cap of $4.83 billion, a PE ratio of -45.16 and a beta of 1.03. PROCEPT BioRobotics has a twelve month low of $24.91 and a twelve month high of $99.34. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.49 and a current ratio of 7.51.

Institutional Trading of PROCEPT BioRobotics

Hedge funds have recently added to or reduced their stakes in the business. Sentry Investment Management LLC acquired a new position in shares of PROCEPT BioRobotics during the third quarter worth approximately $120,000. Harbor Capital Advisors Inc. bought a new position in PROCEPT BioRobotics during the third quarter worth $3,006,000. Americana Partners LLC acquired a new position in PROCEPT BioRobotics during the 3rd quarter valued at $1,494,000. Oak Ridge Investments LLC bought a new stake in PROCEPT BioRobotics in the 3rd quarter valued at $1,942,000. Finally, Nisa Investment Advisors LLC grew its position in PROCEPT BioRobotics by 178.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company’s stock worth $89,000 after purchasing an additional 713 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

Insider Transactions at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $82.51, for a total value of $2,062,750.00. Following the transaction, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at approximately $7,928,880.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $82.51, for a total value of $2,062,750.00. Following the transaction, the chief financial officer now directly owns 96,096 shares in the company, valued at approximately $7,928,880.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Antal Rohit Desai sold 13,305 shares of PROCEPT BioRobotics stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the completion of the transaction, the director now owns 317,518 shares in the company, valued at $24,248,849.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,892 shares of company stock worth $13,946,415. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).